Worth Watching Stocks News Review: Bank of America Corp (NYSE:BAC), ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), STMicroelectronics NV (ADR) (NYSE:STM)

On Thursday, Shares of Bank of America Corp (NYSE:BAC), subtract -1.25% and closed at $15.83 in the last trading session. The last trading range of the stock ranges between $15.60 and $16.09. Hispanic consumers are significantly more likely to engage with mobile to manage their finances, with 78 percent using a mobile banking app, contrast to about half (51 percent) of non-Hispanics. What’s more, nearly three-quarters (69 percent) of the Hispanic community cite digital as their primary method of banking.

These are new findings released recently from the Bank of America Trends in Consumer Mobility Report, exploring mobile trends and banking behaviors among consumers who own a smartphone and have an existing banking relationship at any financial institution. The release of the survey follows the bank’s recent introduction of its mobile app in Spanish.

The report reveals similar insights when examining mobile payments. More than half (56 percent) of Hispanics would use or already use their phone to make purchases at checkout, contrast to just 36 percent of their non-Hispanic counterparts. Seventy-seven percent of Hispanics say they’re likely to use emerging payment methods such as mobile wallets and social media apps, with 72 percent citing they would use or already use their bank’s peer-to-peer payments service.

ContraVir Pharmaceuticals Inc (NASDAQ:CTRV), jumped 21.43% and closed at $1.36 in the last trading session. The last trading range of the stock ranges between $1.25 and $1.51. The company’s Market capitalization is $69.85 million with the total Outstanding Shares of 53.66 million. ContraVir Pharmaceuticals, Inc. (CTRV), a biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies, recently stated positive interim data for CMX157, the Company’s highly potent prodrug of tenofovir, from its ongoing Phase 2a multiple ascending dose clinical study.  The head-to-head study is the first evaluation of CMX157 in HBV patients, and directly compares CMX157 to tenofovir disoproxil fumarate (TDF, Gilead’s Viread®) in chronically infected hepatitis B (HBV) patients.

Patients successfully accomplished both 5 mg and 10 mg cohorts, and interim data stated below are from 10 HBV-infected patients who accomplished 14 days of once-a-day oral dosing of 25 mg of CMX157, and two HBV patients treated for 14 days of oral dosing with 300 mg TDF.  The CMX157 treated patients showed an average 99% reduction in HBV viral load contrast to baseline.  Significantly, the observed antiviral activity for CMX157 is comparable to that observed in TDF-treated patients, but at 1/12th the dose (25 mg CMX157 vs. standard 300 mg TDF).

STMicroelectronics NV (ADR) (NYSE:STM), jumped 0.38% and closed at $7.91 in the last trading session. The last trading range of the stock ranges between $7.83 and $7.99. During the 52-week trading session the minimum price at which share price traded, registered at $5.11 and reached to max level of $8.41. STMicroelectronics (STM.PA), a global semiconductor leader serving customers across the spectrum of electronics applications, declared that it will release third quarter 2016 earnings before the opening of trading on the European Stock Exchanges on Thursday October 27, 2016.

The administration of STMicroelectronics will conduct a conference call on

October 27, 2016 at 9:30 a.m. Central European Time (CET) / 3:30 a.m. U.S. Eastern Time (ET) / 12:30 a.m. U.S. Pacific Time (PT), to discuss performance for the third quarter of 2016.

Leave a Reply

Your email address will not be published. Required fields are marked *